Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 472,402,528
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 33,724 M
  • Annual Income, $ 12,151 M
  • EBIT $ 17,235 M
  • EBITDA $ 18,602 M
  • 60-Month Beta 0.42
  • Price/Sales 13.66
  • Price/Cash Flow 33.15
  • Price/Book 25.21

Options Overview Details

View History
  • Implied Volatility 55.37% ( +0.54%)
  • Historical Volatility 26.23%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 55.37% on 11/20/24
  • IV Low 23.37% on 06/12/24
  • Put/Call Vol Ratio 0.44
  • Today's Volume 35,918
  • Volume Avg (30-Day) 37,659
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 408,673
  • Open Int (30-Day) 334,581

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.90
  • Number of Estimates 3
  • High Estimate 0.94
  • Low Estimate 0.87
  • Prior Year 0.71
  • Growth Rate Est. (year over year) +26.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
99.42 +3.24%
on 11/18/24
116.65 -12.01%
on 10/22/24
-14.69 (-12.52%)
since 10/21/24
3-Month
99.42 +3.24%
on 11/18/24
139.74 -26.55%
on 08/30/24
-32.32 (-23.95%)
since 08/21/24
52-Week
94.73 +8.35%
on 12/11/23
148.15 -30.72%
on 06/25/24
-0.14 (-0.14%)
since 11/21/23

Most Recent Stories

More News
J&J Loses Around $24B in a Month: How to Play the Stock?

J&J JNJ stock has plunged 6.1% in a month, losing almost $24 billion of its market value.Though slowing sales in its MedTech segment, the upcoming patent expiration of its blockbuster drug, Stelara, and...

NVO : 102.64 (-2.50%)
JNJ : 153.45 (+0.22%)
LLY : 753.00 (-0.05%)
KVUE : 23.74 (-0.17%)
Options Playbook: Exploring 3 Iron Condor Trade Ideas Amid Market Volatility

With volatility on the increase, option premiums are elevated which could mean it’s a great time for iron condor trades.

AVGO : 165.19 (+1.19%)
TSLA : 343.30 (+0.37%)
COST : 931.00 (+0.31%)
NVO : 102.64 (-2.50%)
ADBE : 501.00 (+0.30%)
AMGN : 288.28 (+0.14%)
DAL : 64.05 (+0.64%)
COIN : 330.43 (+3.26%)
Is Novo Nordisk Stock a Buy Right Now?

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

NVO : 102.64 (-2.50%)
Buy This Pharma Stock to Bet on the Next Blockbuster Weight-Loss Drug

A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1...

NVO : 102.64 (-2.50%)
LLY : 753.00 (-0.05%)
ZLDPF : 101.0000 (+7.18%)
3 Growth Stocks You Can Buy Right Now Without Any Hesitation

Many investors have a type of acrophobia (the fear of heights). It's not that they're worried about standing at the top of a ladder. Instead, their concern is focused on putting money in stocks when the...

NVO : 102.64 (-2.50%)
LLY : 753.00 (-0.05%)
VRTX : 452.44 (+0.27%)
Prediction: Acquisitions Will Skyrocket Under The Trump Administration. Here's 1 Pharmaceutical Company I Have My Eyes On.

Mergers and acquisitions could make a comeback with Trump headed back to Washington.

VKTX : 51.84 (+0.60%)
NVO : 102.64 (-2.50%)
LLY : 753.00 (-0.05%)
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine, its once-daily...

NVO : 102.64 (-2.50%)
GMAB : 20.47 (+0.10%)
LLY : 753.00 (-0.05%)
ABBV : 168.20 (+0.26%)
Trump Names Anti-Vaxxer Robert Kennedy As Health & Human Services Secretary: Here’s What It Means For Healthcare Stocks

Trump said his HHS Secretary nominee will ensure the public is protected from harmful substances that have aggravated the nation’s health crisis.

NVO : 102.64 (-2.50%)
IBB : 135.32 (+0.36%)
LLY : 753.00 (-0.05%)
MRNA : 36.54 (-1.08%)
AMGN : 288.28 (+0.14%)
XBI : 94.65 (+0.68%)
PFE : 24.86 (-0.32%)
BNTX : 101.98 (-0.16%)
SNY : 47.64 (-0.29%)
US Port Strike Threatens Supply of Popular Weight-Loss Drugs Ozempic, Wegovy, Mounjaro, and Zepbound

The ongoing US port strike on the East and Gulf coasts is causing significant disruptions to pharmaceutical supply chains, particularly for the popular weight-loss drugs Wegovy, Ozempic, Mounjaro, and...

NVO : 102.64 (-2.50%)
LLY : 753.00 (-0.05%)
3 Top Stocks Crushing Q3 Earnings With Strong 2024 Guidance

Hims & Hers, Payoneer, and Astera Labs lead Q3 earnings with standout revenue growth, forecast upgrades, and strategic wins—stocks to watch for growth potential

FVRR : 30.98 (+1.08%)
PAYO : 10.90 (+0.46%)
ALAB : 102.55 (+5.27%)
HIMS : 22.12 (+1.51%)
NVO : 102.64 (-2.50%)
LLY : 753.00 (-0.05%)
UPWK : 15.27 (+1.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 109.08
2nd Resistance Point 107.41
1st Resistance Point 106.34
Last Price 102.64
1st Support Level 103.60
2nd Support Level 101.93
3rd Support Level 100.86

See More

52-Week High 148.15
Fibonacci 61.8% 127.74
Fibonacci 50% 121.44
Fibonacci 38.2% 115.14
Last Price 102.64
52-Week Low 94.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar